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The CAchexia SCOre (CASCO) was described as a tool for the staging of cachectic
cancer patients. The aim of this study is to show the metric properties of CASCO in order
to classify cachectic cancer patients into three different groups, which are associated
with a numerical scoring. The final aim was to clinically validate CASCO for its use
in the classification of cachectic cancer patients in clinical practice. We carried out a
case -control study that enrolled prospectively 186 cancer patients and 95 age-matched
controls. The score includes five components: (1) body weight loss and composition, (2)
inflammation/metabolic disturbances/immunosuppression, (3) physical performance, (4)
anorexia, and (5) quality of life. The present study provides clinical validation for the use
of the score. In order to show the metric properties of CASCO, three different groups
of cachectic cancer patients were established according to the results obtained with
the statistical approach used: mild cachexia (15 ≤ × ≤ 28), moderate cachexia (29
≤ × ≤ 46), and severe cachexia (47 ≤ × ≤ 100). In addition, a simplified version of
CASCO, MiniCASCO (MCASCO), was also presented and it contributes as a valid and
easy-to-use tool for cachexia staging. Significant statistically correlations were found
between CASCO and other validated indexes such as Eastern Cooperative Oncology
Group (ECOG) and the subjective diagnosis of cachexia by specialized oncologists. A
very significant estimated correlation between CASCO and MCASCO was found that
suggests that MCASCO might constitute an easy and valid tool for the staging of the
cachectic cancer patients. CASCO and MCASCO provide a new tool for the quantitative
staging of cachectic cancer patients with a clear advantage over previous classifications.
Keywords: cachexia, wasting, anorexia, weight loss, physical performance, quality of life, classification, score
INTRODUCTION
Cancer cachexia is a syndrome present in a large number of cancer patients that results in body
weight loss, inflammation, reduced physical performance, and decreased quality of life (Evans et al.,
2008; Muscaritoli et al., 2010; Fearon et al., 2011; Cederholm et al., 2016). For instance, according
to Evans et al: “cachexia, is a complex metabolic syndrome associated with underlying illness and
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characterized by loss of muscle with or without loss of fat
mass. The prominent clinical feature of cachexia is weight
loss in adults (corrected for fluid retention) or growth
failure in children (excluding endocrine disorders). Anorexia,
inflammation, insulin resistance, and increased muscle protein
breakdown are frequently associated with cachexia. Cachexia
is distinct from starvation, age-related loss of muscle mass,
primary depression, malabsorption, and hyperthyroidism and is
associated with increasedmorbidity” and it can be classified using
the following criteria: (a) if the patient has a 5% loss of edema-
free body weight during the previous 12 months or less and (b)
the presence of at least three of following five characteristics:
decreased muscle strength, fatigue, anorexia, low fat-free mass
index, or abnormal biochemistry (Evans et al., 2008). Although
several definitions exist, they share common features (Argilés
et al., 2010). In spite of the fact that, in addition to definition,
diagnostic criteria have been established (Evans et al., 2008),
only few studies deal with cachexia staging and classification
of patients (Bozzetti and Mariani, 2009; Gabison et al., 2010).
From this point of view, Fearon et al. (2011) have established a
classification of the syndrome based on inflammation and body
weight loss. Indeed, according to this study: “Severity can be
classified according to the degree of depletion of energy stores
and body protein (lean body mass) in combination with the
degree of on going weight loss. Assessment for classification
and clinical management should include the following domains:
anorexia or reduced food intake, catabolic drive, muscle
mass, and strength, functional, and psychosocial impairment.”
However, this study only allows a qualitative classification of the
different cachectic patients, such as precachexia, cachexia, and
refractory cachexia. A couple of recent papers also proposed a
grading system: (1) incorporating the independent prognostic
significance of both BMI and percentage of weight loss (Martin
et al., 2015) or (2) according to changes on biochemistry (high C-
reactive protein or leukocytes, or hypoalbuminemia, or anemia),
food intake, weight loss, and performance status (Vigano et al.,
2016). CASCO was designed to fulfill the gap of a numerical
classification system and therefore enable the proper quantitative
staging of cachectic cancer patients.
CASCO is mainly based on the following constituents: (1)
body weight loss and composition, (2) inflammation/metabolic
disturbances/immunosuppression, (3) physical performance, (4)
anorexia, and (5) quality of life (Argilés et al., 2011). Table 1
pictures components and measured parameters in more detail.
Body weight loss and composition (BWC) is essential to all
definitions of cachexia. But, the fact that both loss of muscle and
fat tissue coexist in the cachectic patient, stresses the importance
of assessing any changes in relation to lean body mass.
The second component of CASCO is inflammation/metabolic
disturbances/immunosuppression (IMD). Inflammation is a key
feature of the cachectic response (Fearon et al., 1999; Delano
and Moldawer, 2006). It cannot be overlooked that there are also
a number of metabolic disturbances present in many cachectic
patients such as: glucose intolerance, anemia, and low levels
of plasma albumin, most of them included in CASCO (see
Table 1). Immunosuppression may also be an early marker of
cachexia (Faber et al., 2009); therefore, assessment of the immune
TABLE 1 | Components of CASCO.
Component % Measurement Parameter
Body weight loss and
composition (BWC)
40 Body weight
loss
Lean body
mass
Inflammation/metabolic
disturbances/
immunosupression (IMD)
20 Inflammation Plasma CRP
Plasma IL-6
Metabolic
disturbances
Plasma albumin
Plasma pre-albumin
Plasma lactate
Plasma triglycerides
Plasma urea
Anaemia
ROS plasma levels
Glucose tolerance
test/HOMA index altered
Immunosupression Absolute lymphocyte
number
Physical performance
(PHP)
15 Questionnaire of 5
questions related to
physical activity.
Anorexia (ANO) 15 Questionnaire of 4
questions extracted
from SNAQ of St. Louis
VA Medical Centre.
Quality of life (QoL) 10 Questionnaire of 25
questions from
QLQ-C30.
response could also be a valid indication for a cachexia staging
system. The third component relates to physical performance
(PHP). Even with a relative small decrease in muscle mass in
cachexia, there may be a significant decrease in physical activity
which are related to muscle performance (Fouladiun et al., 2007;
Maddocks et al., 2010). Anorexia (ANO) constitutes the fourth
parameter included in CASCO. Indeed, anorexia is present in
cachexia in many diseases (Laviano et al., 2005). A decrease
in food intake, by itself, promotes changes in quality of life
and also conditions many metabolic alterations. Finally, the last
component of CASCO is quality of life (QoL). Quality of life
reflects not just changes in weight and physical performance but
also in metabolic alterations (Fouladiun et al., 2007; Granda-
Cameron et al., 2010). Therefore, it is an important point to
consider.
These five different factors mentioned above, clearly interact
between each other and represent the most important set of
variables to assess the severity of the cachectic syndrome.
Bearing all this in mind, the aim of the present investigation
was to clinically validate CASCO for its use in the classification
of cachectic cancer patients. In addition, a simplified form of
CASCO (miniCASCO) was designed to cope with the limitation
of assessment methods and tools in some clinical centers.
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PATIENTS AND METHODS
Patients
An observational prospective case-control study has been
performed and a total of 186 carcinoma patients and 95 age-
matched control subjects were included (see Participant flow
chart in Figure 1). All the participants in the study were recruited
at the Department of Medical Oncology (University of Cagliari,
Cagliari, Italy) from June 2011 to September 2014. Inclusion
criteria for the cancer patients were histologically confirmed
cancer at any site, age≥18 years old, and the absence of diagnosed
mental disease or severe cognitive deterioration. Inclusion
criteria for the control subjects were absence of neoplasia,
to be over 18 years old and absence of diagnosed mental
disease or cognitive deterioration. Those patients affected by
either non cancer-related nutritional alterations or inflammatory
states leading to body weight loss were excluded from the
study. All the enrolled patients and controls were evaluated
for all parameters with the same methodology descripted
below, reaching the CASCO score for all subjects. The clinical
protocol was fully approved by the Ethics Committee of the
University of Cagliari (Cagliari, Italy; control and patient
subjects) and by Ethics Committee of the University of Barcelona
(control subjects), and all patients and controls signed the
approved written informed consent. Subject characteristics are
presented in Tables 2, 3. Data were extracted, and the quality
of the included studies was evaluated using the STROBE
checklist.
CASCO
The CAchexia SCOre was applied and calculated for each
of the subjects as previously described (Argilés et al., 2011).
The different elements of the score are shown in Table 1.
More information related to the questionnaires and related
calculations can be found in: http://hdl.handle.net/2445/65137
and http://www.ub.edu/cancerresearchgroup/.
MCASCO
The simplified version of CASCO, miniCASCO (MCASCO), was
applied and calculated for each of the subjects. The components
of the MCASCO are shown in Table 5.
Body Weight Loss and Composition (BWC)
Body weight was measured at questionnaire time using an
electronic balance (Health-o-Meter, Bridgeview, IL, USA),
pre-illness weights being obtained by interview or by patient’s
data collection in clinical practices. Lean body mass (LBM)
was assessed through different methods based on the planned
instrumental oncological assessments. These included: (i)
conventional bioelectrical impedance analysis (BIA) (Simons
et al., 1995; Ellis, 2000) using a Bioelectric Impedance Analyser
STA/BIA101 (Akern, Firenze, Italy) in 70% of the patients;
FIGURE 1 | Flow diagram of excluded participants in the CASCO Study with missing or implausible data.
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TABLE 2 | Descriptive statistics for each group.
Group Gender (%) Age Weight Diagnosis Ecog Ps Stage
Controls (n = 95) males = 55% 56.34 ± 0.677
(95*)
76.73 ± 1.58
(93*)
Healthy subjects (n = 75) 0 (100%) NV
females = 45% Patients suffering from
non-neoplastic diseases# (n = 20)
0 (100%) NV
Oncologic patients
(n = 186)
males = 59% 65.27 ± 0.877
(186*)
74.00 ± 1.92
(186*)
Carcinoma (n = 178) 0–1 (38%)
2–3 (62%)
I –IIIA 20% IIIB– IV
80%
females = 41% Mesothelioma, and sarcoma (n = 8)
Results are mean ± S.D and n (the number of patients and controls in parentheses, * indicates the number depending of missing data).# asthma, hypertension, allergic rhinitis, muscle
pain, high cholesterol levels.
TABLE 3 | Carcinoma site diagnosed in cancer group.
Tumor site n Age
Lung 32 70.81 (2.75)
Breast 27 59.78 (2.67)
Head and neck 21 63.19 (2.36)
Colon 17 69.16 (2.16)
Ovary 13 55 (3.79)
Pancreas 11 64.72 (3.87)
Prostate 10 76.3 (1.38)
Upper gastrointestinal 10 63 (3.29)
Rectum 8 68.71 (1.01)
Bile glands 7 69 (5.68)
Endometrium 4 64.5 (4.03)
Liver 3 64.66 (14.30)
Kidney 3 65.33 (5.66)
Other* 17 69.14 (2.49)
Results are mean (S.D) and n the number of cancer patients. *Other carcinoma sites:
peritoneum, cervix, appendix, bladder; and other tumor types: lung sarcoma, pleura
sarcoma, myelofibrosis, pleural mesothelioma and lung heteroplasia.
(ii) dual-energy X-ray absorptiometry (DXA) (Plank, 2005;
Ellegård et al., 2009) using a Hologic Delphi W scanner
(Hologic Inc., Bedford, MA) in 10% of the patients; (iii)
regional computed tomography (CT) scan analysis at L2-L3,
currently considered the highest precision method, trough
measurement by Tomovision Slice-o-Matic Software (Montreal,
Canada) in 20% of the patients. It has to be pointed out that,
although different approaches for the determination of body
composition were used, good correlation have described between
the different methodologies used (Fürstenberg and Davenport,
2011). LBM depletion was defined at baseline accordingly to
standard international range for each method.
Inflammation/Metabolic
Disturbances/Immunosuppression (IMD)
Inflammation
Peripheral venous blood samples were obtained from all patients
and controls by venipuncture (BD Vacutainer, California, USA).
The serum levels of CRP were measured by automatic centralized
nephelometric analyser (AU640, Olympus, Germany), the results
were expressed in mg/L. IL-6 were assessed by ELISA “sandwich”
test, using monoclonal antibodies against specific molecular
epitopes (DRG International, Springfield, NJ, USA by IAM
Consulting, Parma, Italy). The assays were performed in
semiautomatic ELISA analyser (DiaSorin Etilab, Guidonia, Italy)
and the results expressed in pg/mL. The coefficients of variation
for all these methods, in accordance with the quality control
procedures, were always<5%.
Metabolic Disturbances
Metabolic disturbances included the determination of albumin,
pre-albumin, lactate, triglycerides, hemoglobin, urea, reactive
oxygen species (ROS), and HOMA index. Albumin, pre-
albumin, lactate, triglycerides, and urea levels were obtained
during oncological clinical routine by hospital central laboratory
(METROLAB 2300 (Wiener Lab) and the results expressed in
mg/dL for pre-albumin, triglycerides, and urea and g/dL for
albumin. HOMA indexwas calculated for each patient (Matthews
et al., 1985). Determination of plasma levels of ROS were
assessed by reactive oxygen species colorimetric assay (FORT
test, Callegari SpA, Italy; Mantovani et al., 2003; Pavlatou et al.,
2009). Haemoglobin levels were obtained carried out the routine
blood count (Coulter LH750, Beckman-Coulter) and expressed
in g/dL.
Immunosuppression
The immunosuppression was evaluated for each patient by
absolute lymphocyte count, obtained from de routine blood
count. Lymphocyte count has been well recognized as a valid
marker of immune function as well as a prognostic marker
(Bouwhuis et al., 2011). It is included in validated nutritional
tools (such as the Mini Nutritional Assessment; Kabata et al.,
2015; Bourdel-Marchasson et al., 2016). It has to be pointed out
that the total lymphocyte count is not a fully convincing measure
of immunosupression, although it is an “affordable” easy reliable
measurement in a standard hospital. This, therefore, represent a
minor limitation of the score particularly since it only represents
4% of CASCO.
Physical Performance (PHP)
In order to be able to assess the functional state of a cachectic
patient, a physical performance questionnaire was used at the
evaluation time. One question from EORTC QLQ-C30 (question
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number 1) was included. Its use is under permission of 1995
EORTC Quality of Life Group (Aaronson et al., 1993). The text
of the questionnaire is: During the past week: 1. Have you noticed
any particular decrease in the physical activities (i.e., at work, at
home, at leisure etc...) that you normally carry out during the
day?; 2. Have you had any problems doing strenuous activities, like
carrying a heavy shopping bag or a suitcase?; 3. Have you noticed
any loss of handgrip force?; 4. Did you have to put more effort on
climbing stairs?; 5. Have you felt tired after walking approximately
half a kilometer?
Anorexia (ANO)
Anorexia was estimated using a standard questionnaire
[Simplified Nutrition Assessment Questionnaire (SNAQ)]
(Wilson et al., 2005). Its use in CASCO is under permission of St.
Louis GRECC Program of St. Louis VA Medical Centre. The text
of the questionnaire is: 1. My appetite is (very poor, poor, average,
good, very good); 2. When I eat (I feel full after eating only a few
mouthfuls, I feel full after eating about a third of a meal, I feel
full after eating over half a meal, I feel full after eating most of the
meal, I hardly ever feel full); 3. Food tastes (very bad, bad, average,
good, very good); 4. Normally I eat (less than one meal a day, one
meal a day, two meals a day, three meals a day, more than three
meals a day).
Quality of Life (QoL)
Concerning quality of life, CASCO includes 25 questions from
EORTC QLQ-C30 (question numbers: 4–12, 14–17, 19–30).
Questions related to physical performance or food intake were
withdrawn. Its use in CASCO is under permission of 1995
EORTCQuality of Life Group (Aaronson et al., 1993). The text of
the questionnaire is: During the past week: 1. Do you need to stay
in bed or a chair during the day?; 2. Do you need help with eating,
dressing, washing yourself or using the toilet?; 3. Were you limited
in doing either your work or other daily activities?; 4. Were you
limited in pursuing your hobbies or other leisure time activities?; 5.
Were you short of breath?; 6. Have you had pain?; 7. Did you need
to rest?; 8. Have you had trouble sleeping?; 9. Have you felt weak?;
10. Have you felt nauseated?; 11. Have you vomited?; 12. Have
you been constipated?; 13. Have you had diarrhea?; 14. Did pain
interfere with your daily activities?; 15. Have you had difficulty
in concentrating on things, like reading a newspaper or watching
television?; 16. Did you feel tense?; 17. Did you worry?; 18. Did
you feel irritable?; 19. Did you feel depressed?; 20. Have you had
difficulty remembering things?; 21. Has your physical condition or
medical treatment interfered with your family life?; 22. Has your
physical condition or medical treatment interfered with your social
activities?; 23. Has your physical condition or medical treatment
caused you financial difficulties?; 24. How would you rate your
overall health during the past week?; 25. How would you rate your
overall quality of life during the past week?
Statistical Analysis
The Statistical Package for Social Sciences (IBM v.21) was used
to analyse the effects between groups. From a psychometric
perspective, reliability, as an internal consistency parameter, was
estimated using the Cronbach’s α. In addition, Confirmatory
Factorial Analysis (CFA) was conducted to estimate construct
validity through EQS software (v6.0) and normative data were
obtained from a classical point of view with position indexes. All
the statistical techniques were carried out with a significance level
of α = 0.05, correcting for reduction of type I error using the
Bonferroni correction. Finally, cluster analysis between groups
was performed to determine the breakpoints within the scale and
estimate the maximum inertia centroids values. In addition, each
statistical contrast includes the specification of sample size due to
missing data presence.
RESULTS
Analysis of Reliability
The reliability coefficients were estimated using Cronbach’s α
for each of the general factors derived from the questionnaire
(Table 4). The values obtained indicate high reliability for each
of the factors studied
Construct Validity
To estimate the validity of the construct, a model involving
Confirmatory Factor Analysis (CFA) from the CorrelationMatrix
of Pearson was used. The value of the Maximum Likelihood
Estimation (ML), applied to the matrix R, provided initial results
in an adjusted model (χ2 = 675.11; df = 253, p < 0.001;
Comparative Fit Index (CFI) = 0.912; Tucker Lewis Index (TLI)
= 0.941; Root Mean Standard Error (RMSEA) = 0.04; Adjusted
and Standardized Root Mean Residuals (SRMR) = 0.039; 95%
Confidence Interval of SRMR 0.02–0.05; Ratio χ2/df = 3.277).
All indicators, except for the statistical χ2, are compatible with
a valid model, particularly the criterion derived from χ2/df.
Additionally, it should be remarked that each of the latent
factors assumes a significant proportion of the initial variance.
Thus, PHP took 15% while ANO 18% and QoL 45%, the
three representing 78% of the initial value, which is regarded
as a high level of variance accounted for by the reduction of
dimension.
Discriminant Validity
Using the CASCO score the two groups (patients and controls)
were compared in order to estimate the discriminant validity of
the score. The results depicted in Figure 2 show a very significant
difference between groups (t = 145.77, df = 273, p < 0.001;
r = 0.74; Confidence interval of mean difference at 95% between
14.01 and 29.86), indicating a high capacity in the discriminative
ability of the total score. Thus, in the cancer group, the CASCO
TABLE 4 | Reliability estimation through Conbrach’s α.
Variable n* Cronbach’s α
Physical performance 276 0.928
Anorexia 279 0.793
Quality of life 275 0.945
n, the number of patients and controls, * indicates the number depending of missing data.
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FIGURE 2 | Box plot of CASCO total score for each group (patient and
control groups).
value was 32.54 with a standard deviation of 17.58, while in the
control group it was 8.72 with a standard deviation of 3.56.
Concurrent Validity
The correlation between the total CASCO values and those
obtained using a subjective diagnosis of specialized oncologists
(the Oncologist Team from the Department of Medical
Oncology, University of Cagliari, Cagliari, Italy) was established.
The subjective evaluation was based on the following question:
“Before applying CASCO, what is your perception of severity of
patient’s cachexia according to the following scale 0 (normal,
absence of cachexia), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (terminal, evident
cachexia).” Figure 3A shows the scatter plot between the two
variables, characterized by estimating the Spearman correlation
coefficient (rs = 0.412, p < 0.001). The results indicate a clear
positive relationship between the two variables and therefore, a
high level of concurrent validity.Moreover, other external criteria
were used: the Eastern Cooperative Oncology Group (ECOG)
scale, which is a widely used score involved in assessing cancer
patients. Figure 3B shows the scatter plot between the ECOG
and CASCO scores. The Spearman correlation coefficient was:
rs = 0.290, p < 0.001, indicating a clear positive relationship
between the two variables a moderate level of concurrent
validity.
Estimated Classification
Using the CASCO values, three cut-off values were estimated
by means of the application of a hierarchical cluster. Four
groups were originally described, one exactly below the observed
mean, and the other exactly over the mean; and the two last
zones adjusted to every cue (inferior and superior). The three
cut-off values were estimated through the maximization of the
classification function using 95% confidence levels. This was
accomplished by using a similarity matrix according to the
metric properties of the variables and assuming multinormal
distribution. The results show that the four groups were: no
FIGURE 3 | Scatter plots of CASCO against other values of clinical
assessment. (A) Correlation between CASCO and the subjective diagnosis of
specialized oncologists. (B) Correlation between CASCO and the Eastern
Cooperative Oncology Group (ECOG) scale.
FIGURE 4 | CASCO distribution for each of the groups set for the
diagnosis of the severity of cachexia.
cachexia (≤14), mild cachexia (15–28), moderate cachexia (29–
46) and finally, severe cachexia (>46). Figure 4 shows the
distribution observed for each of the groups derived from the
above criterion, indicating that the differences between groups
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were highly significant (F = 743.12, df = 3, 244; p < 0.001; ε =
0.61).
MiniCASCO
A simplified version of CASCO, miniCASCO (MCASCO), was
designed to avoid an excessive amount of clinical measurements
which in some medical centers may be limiting. The components
of the MCASCO are shown in Table 5. The correlation between
the two values, i.e., the original CASCO and the reduced version
MCASCO showed a highly significant coefficient (r = 0.964;
df = 19.50; p < 0.001; Figure 5). This result ensures that
the psychometric properties of CASCO are also present in
the MCASCO test, therefore suggesting a feasible and quick
assessment of the cachexia stage.
DISCUSSION
With the aim of validating the previously published CAchexia
SCOre (CASCO) (Argilés et al., 2011), 186 cancer patients (males
and females in a similar percentage) were recruited in this study
(Table 2). As a reminder, one has to take into consideration that
CASCO includes a combination of the following components: (1)
body weight loss and composition, (2) inflammation/metabolic
disturbances/immunosuppression, (3) physical performance, (4)
anorexia, and (5) quality of life. CASCO was only slightly
modified from the original published version (Argilés et al.,
2011); thus absolute lymphocyte number was taken as a measure
to evaluate immunosuppression (Table 1).
The study includes a heterogeneous cancer patient population.
The most abundant type of cancer was lung carcinoma while
kidney and liver cancer and other carcinoma sites included the
smaller number of patients (see Table 3 for more information).
Control subjects were either healthy (n = 75) or suffering from
non-neoplastic diseases (asthma, hypertension, allergic rhinitis,
muscle pain, high cholesterol levels; Table 2).
Interestingly, other cachexia classification studies also agree
with the results obtained here (Fearon et al., 2011; Vigano
et al., 2016). Indeed, Fearon et al. proposed a classification
of cachectic patients based on identifying the following stages:
FIGURE 5 | Scatterplot of CASCO against MCASCO.
precachexia, cachexia, and refractory cachexia (Fearon et al.,
2011). The additional advantage of the classification proposed
in the present study is that it involves a numerical scale and
therefore can discriminate between patients in any of the three
cachectic groups. Then, the study basically classifies patients into
the following three groups that are associated with a numerical
scoring: mild cachexia, moderate cachexia and severe cachexia.
Conversely, other cachexia classifications do not provide any
discrimination between patients in the same subgroup.
Although the obtained data seem to follow a logical pattern as
compared with previous studies, we undertook a more rigorous
validation based on correlating CASCO with other scores. From
this point of view, we chose the ECOG (Oken et al., 1982) scale,
which is a widely used score involved in assessing cancer patients.
Although ECOG is not an specific scale fo cachexia, it has to be
pointed out that it is widely used in cancer patients and also that
there is no other quantitative cachexia scale at present to establish
an alternative validation. Additionally, a subjective diagnosis
of specialized oncologists was used (the oncologist team from
the Department of Medical Oncology, University of Cagliari,
TABLE 5 | MiniCASCO.
Weight Body weight loss
Lean body mass
Blood
parameters
Plasma albumin Metabolic
disturbances
Anaemia
CRP Inflammation
Absolute lymphocyte number Immunosuppression
Questionnaires Did you have to put more effort on
climbing stairs?
Physical
performance
Have you felt tired after walking
approximately half a kilometer?
My appetite is... Anorexia
When I eat...
Do you need to stay in bed or a chair
during the day?
Quality of life
Where you limited in doing either your
work or other daily activities?
Were you limited in pursuing your
hobbies or other leisure time
activities?
Have you had pain?
Did you need to rest?
Did you feel weak?
Did pain interfere with your daily
activities?
Have you had difficulty in
concentrating on things, like reading
a newspaper or watching television?
Has your physical condition or
medical treatment interfered with your
family life?
How would you rate your overall
health during the past week?
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Cagliari, Italy) and adequate statistically significant correlations
between CASCO and the two scales were observed for both (only
considering the patient values; Figures 3A,B).
In spite of the fact that this study clearly demonstrates
that CASCO is a valid score in the clinical context, it can be
argued that the large number of items (both measurements and
questionnaires) could be a serious obstacle for its routinely use.
Bearing this in mind, we developed a simplified version, the
so-called MiniCASCO (MCASCO), containing only a reduced
number of items (see Table 5). To reduce the number of items
a component analysis was performed. The reduction of items
was done based on factorial loadings of the items in the
component and the discrimination index. This process was done
for each component (PHP, ANO, and QoL). In addition to
body weight loss and composition, blood measurements include
only albumin, anemia, CRP, and absolute lymphocyte number
(Table 5); together with a questionnaire containing two questions
related with PHP, two related with ANO and 11 related with QoL
(Table 5). It can be seen that there is an excellent correlation
between CASCO and MCASCO (r = 0.964; Figure 5).
Altogether, the information presented here, first, serves to
clinically validate CASCO for the staging of cachectic cancer
patients and second, it provides a significantly plausible tool
(MCASCO) to perform the staging in almost any clinical setting,
since the majority of hospitals and clinics have access to the
determination of the parameters included in MCASCO. It has to
be pointed out that CASCO and MCASCO provide a new tool
for the quantitative staging of cachectic cancer patients with a
clear advantage over previous classifications (Fearon et al., 2011;
Martin et al., 2015; Vigano et al., 2016).
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